Physician profile
Timothy S Coss
NPI 1720071699
$8,668.12
in general payments reported to CMS, 2019-2025
45 companies · $1,896 in 2025
The $1,896 reported for 2025 was more than what 93% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,641 · 2020: $360 · 2021: $576 · 2022: $911 · 2023: $1,388 · 2024: $1,896 · 2025: $1,896.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,180.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,179.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,204.06 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $1,103.97 | 2019-2025 | Ubrelvy, Qulipta, Vraylar |
| Astrazeneca Pharmaceuticals Lp | $828.98 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Pfizer INC. | $772.11 | 2019-2025 | |
| Lilly USA, LLC | $669.89 | 2019-2025 | Zepbound, Jardiance, Mounjaro |
| Amgen INC. | $559.60 | 2019-2025 | Repatha, Evenity, Otezla |
| Glaxosmithkline, LLC. | $402.92 | 2019-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Gilead Sciences, INC. | $260.91 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $218.55 | 2019-2024 | Xarelto |
| Astellas Pharma US INC | $200.80 | 2019-2025 | Veozah, Myrbetriq |
| Viiv Healthcare Company | $170.81 | 2022-2025 | Apretude |
| E.R. Squibb & Sons, L.L.C. | $166.13 | 2021-2025 | Camzyos, Eliquis |
| Boehringer Ingelheim Pharmaceuticals, INC. | $165.06 | 2019-2025 | Jardiance |
| Merck Sharp & Dohme LLC | $157.57 | 2019-2025 | M-M-R II, Gardasil, Capvaxive |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $154.58 | 2019-2023 | Xifaxan, Trulance |
Show all 45 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Timothy Coss listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.